Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
Abstract Metaplastic breast carcinoma (MpBC) is a rare special histologic subtype of breast carcinoma characterized by the presence of squamous and/or mesenchymal differentiation. Most MpBCs are of triple-negative phenotype and neoadjuvant chemotherapy (NAC) is frequently utilized in patients with M...
Saved in:
Main Authors: | Willard Wong, Edi Brogi, Jorge S. Reis-Filho, George Plitas, Mark Robson, Larry Norton, Monica Morrow, Hannah Y. Wen |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/dfb94e25ff8d460f8dd36265079a5e88 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer
by: Edaise M. da Silva, et al.
Published: (2021) -
Metaplastic breast carcinoma with upper limb gangrene
by: Rajan R, et al.
Published: (2017) -
A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
by: Kunnuru SKR, et al.
Published: (2020) -
The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
by: San-Gang Wu, et al.
Published: (2020) -
Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy
by: Sales ACV, et al.
Published: (2020)